DealZone

Sanofi-Aventis says new drug pipeline is delivering

April 3, 2008

Marc Cluzel, head of research at French drugmaker Sanofi-Aventis, talks to Reuters’ Ben Hirschler about the outlook for the company’s pipeline of new drugs.

The group had a major setback last June when U.S. experts recommended against approving its weight-loss drug Acomplia, also known as Zimulti, because of worries it might give some patients suicidal thoughts.But Cluzel says there are other exciting drugs in development, with half a dozen new products set to be submitted to regulators for approval this year.

The company has been stepping up its deals with biotech recently, clinching a major tie-up with Regeneron and signing a cancer vaccine deal with Oxford BioMedica that some analysts believe might eventually lead to a takeover.

Post Your Comment

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/